SciBase

SciBase
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden.

Contacts

Pia Renaudin
pia.renaudin@scibase.com

SciBase publishes the Annual report for 2025

Mon, Apr 27, 2026 16:00 CET

SciBase hereby announces that the Annual report for 2025 is available at the Company’s website www.scibase.com.A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFOTel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com Certified Advisor: DNB Carnegie Investment Bank AB (publ)Tel: +46 8 588 68 570Email: certifiedadviser@carnegie.se The information was submitted for

There are no items matching the current filter

There are no more items matching the current filter

About Us

Contacts

Links

SciBase publishes the Annual report for 2025

Subscribe

Media

Youtube

Share

About Us

Contacts

Links

SciBase publishes the Annual report for 2025

Subscribe

Media

Youtube